Xenon Pharmaceuticals
XENE· Manufacturing· Fiscal year ends in December
CEO pay in FY2022Stock +26.2% in FY2022
Ian Mortimer is the CEO of Xenon Pharmaceuticals and was paid $9.2M in FY2022 (Dec), up 137%.
Pay$100 in the stock at the end of FY20 → $256
Executives6
See all- 1Ian MortimerPresident and Chief Executive OfficerFY2022
- 2Christopher KenneyChief Medical OfficerFY2022
- 3Sherry AulinFormer Chief Financial OfficerFY2022
- 4Andrea DiFabioChief Legal Officer and Corporate SecretaryFY2023
- 5Darren Cline, M.B.A.Chief Commercial OfficerNot disclosed
- 6Thomas KellyChief Financial OfficerNot disclosed
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allXenon Pharmaceuticals paid its one named executive on file $1.7M in FY2023 (Dec).
| Name | |||
|---|---|---|---|
| Andrea DiFabioChief Legal Officer and Corporate Secretary | Not disclosed | ||
| Ian MortimerPresident and Chief Executive Officer | Not disclosed | ||
| Christopher KenneyChief Medical Officer | Not disclosed | ||
| Sherry AulinFormer Chief Financial Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Xenon Pharmaceuticals. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 22, 2026 | FY2025 |
| Annual report | 10-K | Feb 26, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 24, 2025 | FY2024 |
| Annual report | 10-K | Feb 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Feb 29, 2024 | FY2023 |
